 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 1 of 34  
Ascorbic Acid, Hydrocortisone, and Thiamine  in Sepsis and Septic Shock  
– A Randomized, D ouble -Blind, Placebo -Controlled  Trial 
 
Acronym: Ascorbic acid, Corticosteroids, and Thiamine  in Sepsis  (ACTS) Trial 
 
CLINICAL TRIAL PROTOCOL  
 
             Version 2.4 
December 13, 2018 
            IND: 136882  
 
 
Clinical Trials.Gov Identifier: [STUDY_ID_REMOVED]  
 
Principal investigator : 
Michael W. Donnino, MD  
Director of Center for Resuscitation Science  
Associate Professor of Medicine, Harvard Medical School  
Attending Physician in Emergency and Critical Care Medicine, BIDMC  
 
Beth Israel Deaconess Medical Center  
West Clinical Campus 2nd Floor  
One Deaconess Road, Boston MA 02215  
Phone: 617 -754-2295  
Fax: 617 -754-2350  
Email: mdonnino@bidmc.harvard.edu  
 
Funded By:  
Open Philanth ropy Project  (https://www.openphilanthropy.org/ ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 2 of 34  
SYNOPSIS  ................................ ................................ ................................ ................................ ......................... 5 
TRIAL OVERVIEW  ................................ ................................ ................................ ................................ ............ 6 
STEERING COMMITTEE  ................................ ................................ ................................ ................................ 7 
TRIAL SITES  ................................ ................................ ................................ ................................ ...................... 8 
1. BACKGROUND AND SIGNIFICANCE  ................................ ................................ ................................ ......9 
1.1 Scope of the Problem  ................................ ................................ ................................ ............................. 9 
1.2 Existing Interventions  ................................ ................................ ................................ ............................. 9 
1.3 The combination of vitamin C, hydrocortisone, and vitamin B1 may improve outcomes  ............ 9 
1.4 Physiologic Rationale  ................................ ................................ ................................ ............................. 9 
2. TRIAL DESIGN  ................................ ................................ ................................ ................................ ...........  10 
2.1 Overview  ................................ ................................ ................................ ................................ ................  10 
2.2 Allocation  ................................ ................................ ................................ ................................ ...............  10 
2.3 Intervention  ................................ ................................ ................................ ................................ ...........  10 
2.3.1 Vitamin C, Hydrocortisone, and Vitamin B1  ................................ ................................ .............  10 
2.3.2 Placeb o................................ ................................ ................................ ................................ ...........  10 
2.4 Blinding  ................................ ................................ ................................ ................................ ..................  10 
2.5 Regulatory Issues  ................................ ................................ ................................ ...........................  10 
3.  SE TTING AND PARTICIPANT POPULATION  ................................ ................................ ....................  11 
3.1 Setting  ................................ ................................ ................................ ................................ ....................  11 
3.2 Inclusion criteria  ................................ ................................ ................................ ................................ ... 11 
3.3 Exclusion criteria  ................................ ................................ ................................ ................................ .. 11 
3.4 Pregnancy  ................................ ................................ ................................ ................................ .............  11 
4. TRIAL PROCEDURES  ................................ ................................ ................................ ..............................  12 
4.1 Participant Identification  ................................ ................................ ................................ ......................  12 
4.2 Consent procedures  ................................ ................................ ................................ ............................  12 
4.3 Randomization  ................................ ................................ ................................ ................................ ...... 12 
4.4 Drug p reparation and administration  ................................ ................................ ................................ . 13 
4.4.1 Contingencies and Participant Withdrawal  ................................ ................................ ...............  13 
4.5 Specimen collection procedures  ................................ ................................ ................................ ........  13 
4.5.1 Timing and volume of blood draw  ................................ ................................ ..............................  13 
4.5.2 Specimen samples  ................................ ................................ ................................ .......................  13 
4.5.3 Biomarker tube initial processing and shipping  ................................ ................................ ........  14 
4.6 Study flow diagram  ................................ ................................ ................................ ..............................  14 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 3 of 34 4.7 General Sepsis Management  ................................ ................................ ................................ .............  14 
4.8 Glucometer use during the study period  ................................ ................................ ..........................  15 
5. OUTCOMES  ................................ ................................ ................................ ................................ ...............  15 
5.1 Definitions  ................................ ................................ ................................ ................................ ..............  15 
5.1.1 Primary Outcome  ................................ ................................ ................................ ..........................  15 
5.1.2 Key Secondary Outcomes  ................................ ................................ ................................ ...........  15 
5.2 Rationale for Outcomes  ................................ ................................ ................................ ......................  16 
5.3 Additional Secondary Outcomes  ................................ ................................ ................................ .......  16 
5.3.1 Additional secondary outcomes  ................................ ................................ ................................ .. 16 
5.3.2 90 -day follow -up for Quality of Life assessment  ................................ ................................ ...... 17 
5.4 Safety  ................................ ................................ ................................ ................................ .....................  17 
5.4.1 Definitions  ................................ ................................ ................................ ................................ ...... 17 
5.4.2 Specific adverse event data collection  ................................ ................................ ......................  17 
5.4.3 Adverse Event Reporting  ................................ ................................ ................................ .............  18 
5.4.5 Safety Monitoring Labs  ................................ ................................ ................................ ................  18 
6. SAMPLE SIZE CALCULATION AND STATISTICAL ANALYSIS PLAN  ................................ ...........  18 
6.1 Sample size calculation  ................................ ................................ ................................ .......................  18 
6.2 Statistical analysis plan  ................................ ................................ ................................ .......................  19 
6.2.1 General considerations  ................................ ................................ ................................ ................  19 
6.2.2 SOFA score and renal failure  ................................ ................................ ................................ ...... 19 
6.2.3 30 -day mortality  ................................ ................................ ................................ .............................  20 
6.2.5 Subgroup analyses  ................................ ................................ ................................ .......................  20 
6.2.6 Statistical stopping criteria  ................................ ................................ ................................ ...........  20 
7. DATA COLLECTION AND MANAGEMENT  ................................ ................................ ..........................  20 
7.1 Data collection process  ................................ ................................ ................................ .......................  20 
7.2 Variables  ................................ ................................ ................................ ................................ ................  20 
7.3 Data quality and validity  ................................ ................................ ................................ ......................  21 
7.4 Data storage and security  ................................ ................................ ................................ ...................  21 
8. ETHICAL CONSIDERATIONS  ................................ ................................ ................................ .................  21 
8.1 Risks and Benefits  ................................ ................................ ................................ ...............................  21 
8.1.1 Potential benefits  ................................ ................................ ................................ ..........................  21 
8.1.2 Potential harms  ................................ ................................ ................................ .............................  21 
9. MONITORING ................................ ................................ ................................ ................................ .............  23 
9.1 Institutional Review Board (IRB)  ................................ ................................ ................................ ........  23 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 4 of 34 9.2 Data Safety and Monitoring Board (DSMB)  ................................ ................................ .....................  23 
10 CLINICAL MONITORING PLAN  ................................ ................................ ................................ .............  24 
11. TIMELINE AND ENROLLMENT  ................................ ................................ ................................ ............  25 
11.1 Timeline  ................................ ................................ ................................ ................................ ...............  25 
11.2 Screening  & Enrollment  ................................ ................................ ................................ ....................  25 
12. FUNDING  ................................ ................................ ................................ ................................ ..................  26 
13. PUBLICATION  ................................ ................................ ................................ ................................ ..........  26 
14. DATA SHARING  ................................ ................................ ................................ ................................ ...... 26 
15. TASKS AND RESPONSIBILITIES  ................................ ................................ ................................ ........  26 
References  ................................ ................................ ................................ ................................ ......................  28 
Appendices  ................................ ................................ ................................ ................................ ......................  33 
Appendix 1: Abbreviations  ................................ ................................ ................................ .........................  33 
Appendix 2: CAM -ICU Form  ................................ ................................ ................................ .....................  34 
 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 5 of 34 SYNOPSIS  
 
The “Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) ” trial is a multi -center, double -
blind, randomized clinical trial that aims to determine the impact  of Vitamin C, Hydrocortisone, and 
Vitamin B1  vs. Placebo on organ injury and mortality on participant s with sepsis and septic shock. 
The trial will be conducted in accordance with all applicable national and international laws, 
regulations, and guidelines The trial and this protocol is developed in accordance with the 
International Conference on Harmonizati on (ICH) guidelines1-3 and the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) statement4,5. The principal investigator wrote 
the protocol with input from the steering committee. Any substantial change s or amendments to the 
protocol will be clearly documented and communicated to all relevant parties.  
 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 6 of 34 TRIAL OVERVIEW  
 
Title Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis  and 
Septic Shock – A Randomized, Double -Blind, Placebo -
Controlled Trial (The ACT S Trial)  
Clinical Trials Number  [STUDY_ID_REMOVED]  
Sources of monetary or 
material support  Open Philanthropy Project  
(https://www.openphilanthropy.org/)   
Study Sites  12-sites in the United States  
Condition studied  Sepsis  and septic shock  
Interventions  Vitamin C ( 1.5g every 6 hours x 4 -days) , hydrocortisone  
(50mg every 6 hours x 4 -days),  and Vitamin B1  (100mg 
every 6 hours x 4 -days)  
Comparator  Placebo   
Inclusion criteria  • Adult participant  (age ≥ 18 years)  
• Suspected (cultures drawn and antibiotic given) or 
confirmed (via culture results) infection  
• Receiving vasopressor (norepinephrine, 
phenylephrine, epinephrine, dopamine, vasopressin , or 
angiotensin II )  
Exclusion criteria  • Member of a protected population (pregnant, prisoner)  
• Known history of kidney stones within the past 1 year  
• End stage renal disease (ESRD) requiring  dialysis  
• Known history of G6PD deficiency  
• Known history of Hem ochromatosis  
• Comfort Measures Only status  
• Anticipated death within 24 -hours despite maximal 
therapy (as determined by the enrolling physician)  
• Receiving supplemental vitamin B1  in a dose greater 
than that contained in a multivitamin (<2mg)  
• Clinical indication for steroids (e.g. chronic use) as 
determined by the clinical team providing this drug  
• Clinical indication for ascorbic aci d supplementation in 
any form  
• Clinical indicatio n for vitamin B1  as determined by the 
clinical team providing this drug  
• Known allergy to vitamin C, hydrocortisone, or vitamin B1  
Study type  Interventional  
Allocation: Randomized  (1:1) 
Intervention model: Parallel group  
Masking: Double -blind  
Target sample size  200 Participants  (100/arm)  
Primary outcome  Change in the Sequential Organ Failure Assessment 
(SOFA) score between enrollment and 72 -hours  
Key secondary outcomes  Incidence of renal failure  during index ICU stay  
30-day mortalit y 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 7 of 34 STEERING COMMITTEE  
 
Michael Donnino, M.D.   
Associate Professor  of Medicine  
Director, Center for Resuscitation Science  
Beth Israel Deaconess Medical Center  
Harvard Medical School  
 Paul E. Marik, M .D. 
Professor of Medicine  
Chief, Division of Pulmonary and Critical 
Care Medicine  
Eastern Vi rginia Medical School  
 
Ari Moskowitz, M .D. 
Attending, Pulmonary and Critical Care Medicine  
Beth Israel Deaconess Medical Center  
Harvard Medical School  
 Katherine Berg, M .D. 
Assistant Professor of Medicine  
Beth Israel Deaconess Medical Center  
Harvard Medical School  
 
Lars W. Andersen, M .D., MPH, Ph .D 
Associate Professor of Medicine  
Research Center for Emergency Medicine  
Department of Clinical Medicine  
Aarhus University and Aarhus University Hospita l 
 Anne Grossestreuer, Ph .D. 
Instructor in Emergency Medicine  
Beth Israel Deaconess Medical Center  
Harvard Medical School  
 
Michael N. Cocchi , MD  
Assistant Professor of Emergency Medicine  
Beth Israel Deaconess Medical Center  
Harvard Medical School  
 Joseph Miller, MD  
Attending, Emergency Medicine  
Department of Emergency Medicine  
Henry Ford Hospital  
 
Conflicts of interest  
The members of the steering committee have no financial conflicts of interest related to the current 
trial.  
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 8 of 34 TRIAL SITES  
 
Coordinating Center  
Beth Israel Deaconess Medical Center  
330 Brookline Avenue  
Boston, MA 02215  
Site Investigator: Michael W. Donnino, MD  
 
Enrolling Sites * 
 
Hospital Name  Location  Site Principal Investigator  
Henry Ford Hospital  Detroit, MI  Bruno DiGiovine , MD  
DMC -Detroit Receiving Hospital  Detroit, MI  Rob Sherwin , MD  
DMC -Sinai -Grace Hospital  Detroit, MI  Rob Sherwin , MD  
Harper Hospital  Detroit, MI  Rob Sherwin, MD  
UT Health, The University of Texas  
Health Science Center  Houston, TX  Pratik Doshi , MD  
Mayo Clinic  Phoenix, AZ  Ayan Sen , MD  
Beth Israel Deaconess Medical 
Center  Boston, MA  Ari Moskowitz , MD 
Beaumont Hospital  Royal Oak, MI  Ron Otero , MD  
Brigham and Women’s Hospital  Boston, MA  Peter Hou , MD 
Long Island Jewish Hospital Center  
- Queens  New York, NY  Maksim Korotun, MD ; Jonathan 
Gong, MD  
Long Island Jewish Hospital Center  
– Hyde Park  New York, NY  Ayelet Hilewitz, MD ; Jonathan 
Gong, MD  
Mount Auburn Hospital  Cambridge, MA  Jessica McCannon , MD  
Univer sity of Pittsburgh  Pittsburgh, PA  David Huang, MD  
South Shore Hospital  Weymouth, MA  Mark Hershey, MD  
*Depending on study progress, sites may be added or removed in the future.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 9 of 34 1. BACKGROUND AND SIGNIFICANCE  
1.1 Scope of the Problem   
The worldwide incidence of sepsis has been estimated at more than 23 million cases6 and sepsis 
contributes to more than a third of all hospital deaths in the United States.7,8 Mortality for those in 
septic shock with elevated lactate is more than 40%.9 In addition to high short -term mortality, sepsis  
is associated with significant post -discharge morbidity an d mortality.10-15 The economic burden for 
participant s suffering from sepsis  is staggering with an estimated yearly financial burden of $17 
billion.16 Treatments are generally limited to antibiotics and  intravenous  fluids while providing support 
to maintain organ function.17,18  
 
1.2 Existing Interventions  
To date, numerous interventions have been tested for participant s with sepsis  and septic shock with 
limited, if any, success.19-22 Recently, three large studies found no benefit from early goal directed 
therapy over usual care in emergency department participant s with  sepsis.23-25 Other  recent studies 
focusing on hemodynamics, fluid therapy, and transfusions have also failed to show a significant 
benefit in this participant  population.26-28 Previous studies focusing on immunomodulary therapies or 
drotrecogin alfa have likewise shown disappointing results.29-35  
 
1.3 The combination of v itamin C, hydrocortisone, and vitamin B1  may improve outcomes  
In a before -and-after study exploring the effects of the combination of vitamin C, hydrocortisone, and 
vitamin B1  in a cohort of participant s with sepsis  and septic shock, Marik et. al. found a remarkable 
improvement in time to shock reversal  (18.3 ± 9.8 h ours vs. 54.9 ± 28.4 hours ), organ injury (ΔSOFA 
4.8 ± 2.4 vs. 0.9 ± 2.7 ), and mortality (8.5% vs. 40. 4%) following implementation of the drug ‘cocktail’ 
as compared to before implementation  even after adjusting for potential confounders .36 This study 
joins other promising trials of individual elements of this drug combination. In a t rial of vitamin B1  in 
septic shock, there was  a substantial reduction in mortality and organ injury (particularly kidney 
injury) in those with vitamin B1  deficiency and septic shock who were given vitamin B1  as compared 
to placeb o.37,38 In addition,  several studies of vitamin C alone have shown promis e in critically ill 
populations39-42 and a recent meta -analysis of corticosteroids in sepsis suggests potential benefit.43 
 
1.4 Physiologic Rationale  
The combination of vitamin C, hydrocortisone, and vitamin B1  is hypothesized to improve outcomes 
in sepsis through a number of mechanisms.36 Vitamin C is an important contributor to endothelial 
integrity and severe deficiency states (e.g. scurvy) can result in endothelial breakdown with resultant 
vascular leak and edema.44,45  In addition, vitamin C is a potent anti -oxidant and is integral to 
endogenous vasopressor synthesis .36 Hydrocortisone,  a potential adjunctive therapy in septic 
shock46,47, may act synergistically with vitamin C.48,49 Vitamin B1 , a key cofactor of pyruvate 
dehydrogenase, is a critical component of metabolic dysfu nction without which a shift towards 
anaerobic energy production occurs.50 Vitamin B1  is also a necessary component of the pentose 
phosphate pathway, which plays a role in reducing oxidative stress.51,52 While the physiologic effects 
of these drugs given in combination is not entirely known, we hypothesize that there will be 
synergistic effects with respect the metabolic resuscitation of sepsis.  
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 10 of 34 2. TRIAL DESIGN  
2.1 Overview  
This will be a n investigator -initiated,  multicenter, randomize d, placebo -controlled, parallel group, 
double -blind , superiority  trial of vitamin C, hydrocortisone, and vitamin B1 vs. placebo in participant s 
with sepsis  and septic shock . A total of 200 adult participant s will be enrolled . The primary outcome 
will be the change in SOFA score between enrollment and 72 -hours . Key secondary outcomes 
include the incidence of renal failure during the index ICU stay and survival at 30 days . 
 
2.2 Allocation  
Participant s will be randomized in a 1:1 ratio to either the combination of vitamin C, hydrocortisone, 
and vitamin B1  or placebo i n blocks with  random sizes of 2  or 4. The randomization will be stratified 
according to site.53 An independent statistician will create the randomi zation list using a random 
number g enerator . The complete list will only be shared with an independent pharmacy consultant , 
who will not be involved  in clinical car e. The pharmacy consultant and the independent statistician 
will both store the randomization list.  The research pharmacy at each enrolling site will receive a 
site-specific randomization list.   
 
2.3 Intervention  
2.3.1 Vitamin C, Hydrocortisone, and Vitamin B1  
The study drugs will consist of vitamin C ( 1.5g every 6 hours x 4 -days) , hydrocortisone  (50mg every 6 
hours x 4 -days),  and vitamin B1 ( 100mg every 6 hours x 4 -days) . 
 
2.3.2 Placebo  
The placebo will consist of matching volumes of normal saline (0.9% NaCl).  See below section 4.4 
for specifics of drug and placebo preparation.  
 
2.4 Blinding  
The trial will be double -blind; participant s, investigators, and the clinical team will be blinded to the 
allocation. Only the pharmacy providing the study drug  will be aware of the allocation. The 
pharmacy will not be involved  with clinical care  or outcome evaluation .  
 
As vitamin C possess a yell ow tinge, the bags containing the vitamin C/placebo will be covered with 
light-protective bags.  In testing, after dilution there is not distinguishing characteristics of the vitamin 
C vs. placebo in the IV tubing.  Vitamin C, hydrocortisone, and vitamin B1 are not known to have 
distinctive rapid effects which could lead to unblinding.  
  
The decision to unblind  will be at the complete discretion of the treating physician and clinical team. 
If a clinical team wishes to unblind a participant (e.g. if anaphylaxis occurs), they will contact the 
research pharmacy who will reveal the study group to the clinical team  (but the research team will 
remain blinded) . However, w e do not expect many scenarios where emergency unblinding will be 
necessary. In  case unblinding occurs, the reason(s) will be clearly documented  in the case report 
form. The patient will no longer recei ve study medications, but will be followed for outcomes .  
 
2.5 Regulatory Issues  
An Investigation al New Drug (IND) application was submitted to and approved by the Food and 
Drug Administration (FDA) for the study of vitamin C, hydrocortisone, and vitamin B1 in  sepsis  and 
septic shock  (IND # 136882 ). 
 
The trial has been registered on ClinicalTrials.gov: [STUDY_ID_REMOVED]  
 
 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 11 of 34 3.  SETTING AND PARTICIPANT  POPULATION  
3.1 Setting  
The trial will be conducted at approximately  13 hospitals in the United States . Additional sites might 
be recruited if needed.  
 
3.2 Inclusion criteria  
Inclusion  criteria:  
1) Adult participant  (age ≥ 18 years)  
2) Suspected (cultures drawn and antibiotic given) or confirmed (via culture results) infection  
3) Receiving (continuous infusion) vasopressor (norepinephrine, phenylephrine, epinephrine, 
dopamine,  angiotensin II,  or vasopressin)  
a. Hypotension related primarily to sepsis as opposed to another cause of hypotension 
(e.g. bleed, cardiogenic shock)  
 
3.3 Exclusion criteria  
Exclusion criteria : 
1) Member of a protected population (pregnant, prisoner)  
2) Known history of kidney stones within the past 1 year  (not including incidentally noted stones 
noted on imaging  studies ) 
3) End stage renal disease requiring dialysis  (hemodialysis or peritoneal dialysis)  
4) Known history of G6PD deficiency  
5) Known history of Hem ochromatosis  
6) Comfort Measures Only status  
7) Anticipated death within 24 -hours despite maximal therapy (as determined by the enrolling 
physician)   
8) Receiving supplement al vitamin B1  in a dose greater than that contained in a multivitamin 
(<2mg)  
9) Clinical indication for steroids (e.g. chronic use) as determined by the clinical team providing this 
drug 
10) Clinical indication for ascorbic acid supplementation in any form  
11) Clinical indication for vitamin B1  as determined by the clinical team providing this drug  
12) Known allergy to vitamin C, hydrocortisone, or vitamin B1  
 
Justification of Inclusion and Exclusion Criteria:  The inclusion criteria were chosen to isolate a septic 
participant  population with high risk of organ injury and death. The exclusion criteria were chosen to 
minimize the risk of potential harm and to ensure that participant s enrolled do not already have 
chronic end -stage renal failure with a high likelihood of early nee d for renal replacement therapy. By 
evaluating this high -risk population (i.e., most likely to die), we will target those most likely to benefit 
and therefore increase the probability of showing efficacy.19  
 
3.4 Pregnancy  
Hydrocortisone is considered pregnancy class C on the basis of animal studies showing an 
association  between prenatal parenteral hydrocortisone use and risk of cleft -palate. In addition, 
there are concerns about effects of hydrocortisone on fetal growth and the possibility of neonatal 
adrenal insufficiency.  The effect s of high -dose vitamin C and thiamine  in pregnancy are not entirely  
known. As such, participant s who are pregnant will be excluded from the study. Prior to enrollment, 
all participant s of potentially child -bearing potential (women aged < 45 years54) will be required to 
have a negative serum or urine HCG test  (generally performed as standard -of-care) .  
 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 12 of 34 We will additionally  inform all women of child -bearing potential who are randomized in this study  
that we recommend th ey remain  abstinent  or use two forms of birth control during the study period 
and for a period of 48-hours after the last dose of study drug .  
 
4. TRIAL PROCEDURES  
4.1 Participant Identification  
Screening will be performed in the emergency department a nd intensive care units (ICUs) with the 
assistance of electronic screening mechanisms . Detailed screening logs, with reason(s) for exclusion 
will be kept at each site and reported in the final publication.  
 
We anticipate that all patients, as part of sta ndard -of-care for the septic patient, will have a urine or 
serum HCG test performed (if a female of child -bearing age) . If this test is not sent as part of standard -
of-care, it should be sent prior to consent.   
 
4.2 Consent proc edures  
Informed, written co nsent will be obtained for all participants prior to enrollment.  
 
After it is determined that they meet all inclusion criteria and no exclusion criteria, the participant  (or 
legally authorized representative [LAR]  if the participant  is not able to provide  consent) will be 
approached for written informed consent by a physician co -investigator from the team. The 
investigator  will provide the participant /representative  information regarding the background and 
significance of the study, eligibility criteria, and a description of the protocol. To ensure we are 
correctly identifying the potential participant’s  LAR, we communicate with  members of  the clinical 
team . The cons ent process may need to be modified based on site -specific IRB recommendations.  
 
The name of the study investigator obtaining consent will be clearly documented, and this person will 
sign the informed consent document and provide the date  and time  of thei r signature. If a physician 
is performing remote consent, then a copy of the consent form will be signed as soon as he/she is 
physically present. Signed copies of the consent form will be given to the participant/surrogate, and 
the original consent documen t will be stored in the secure study file. In obtaining and documenting 
informed consent, each investigator will comply with the applicable regulatory requirements and 
adhere to the ethical and Good Clinical Practice principles that have their origin in th e Declaration of 
Helsinki.  
 
4.3 Randomization  
After consent is obtained, the research t eam will notify the local research pharmacy. The research 
pharmacy will be in possession of the randomization list and will determine which arm (intervention 
vs. placebo) the participant  will be enrolled in.  
 
Patients should be randomized , consented,  and enrolled in the study as soon as possible after 
meeting inclusion criteria. Patients should not be consented  if it has been >24hours since the 
patient met inclusion criteria  (i.e. start of vasopressors) . At the time of randomization and stud y drug 
administration, the patient should still be receiving a vasopressor. The patient should not be given 
study drug if the vasopressor has been stopped (e.g. patient met inclusion criteria overnight but 
could not be consented for logistical reasons and then improves to the point of no longer requiring a 
vasopressor) . In this scenario, the paitent will be entered into the dabase as consented but not 
enrolled.  
 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 13 of 34 4.4 Drug preparation and administration  
The vitamin C and vitamin B1 will be mixed together in 100ml of normal saline and administered 
intravenously over 45-60 minutes. The hydrocortisone will be given intravenously as a push -dose  in 
1ml of saline  over 1-2 minute s. The placebo will be given using techniques and volumes matching 
those of the study me dications.  
 
All study medications will be continued for 4 -days  or until the participant  expires or leaves the 
intensive care unit.  
 
4.4.1 Contingencies  and Participant  Withdrawal  
• In the unlikely event that a participant  is discharged alive from the hospital prior to 4 days  after 
enrollment , all study medications will be stopped .The participant  will remain in the study and will 
be followed for outcomes.  
• Hydrocortisone is occasionally used for refractory septic shock. If t he clinical team opts to provide a 
participant  hydrocortisone, the hydrocortisone will be given open -label but the vitamin C/B1 will 
remain randomized and blinded. In this case,  the research team will ensure that study 
hydrocortisone/placebo is replaced by  open -label hydrocortisone . The participant  will remain in 
the study and will be followed for outcomes.  
• If the clinical team decides to give the participant vitamin B1 for clinical purposes, the study drug 
will be continued (including thiamine) as long as the total maximum dose of vitamin B1 is 
≤1,500mg/day. 1,500mg day is a standard dose for Wernicke’s ence phalopathy at many 
institutions and has not been associated with any increased harm.  
• If the clinical team decides to give the participant  vitamin C for clinical purposes, further 
administration of study meds will be stopped. The participant  will remain in  the study and will be 
followed for outcomes.  
• If a participant  withdraws from the study, further administration of study meds will be stopped. 
Data collected prior to withdrawal  will be maintained but additional data will not be collecte d.   
 
4.5 Specimen  collection procedures  
4.5.1 Timing  and volume of blood dra w 
All participant s will have a blood samples collected at four time-points  and urine samples at two 
time-points (if not already available as part of routine clinical care) . Blood will be obtained by 
venipuncture, or from an existing venous or arterial catheter. Urine will be collected via clean catch 
urine or via catheter.  
 
Specimen Collection  Time Points  
1. T1=0 hrs (just before study drug administration)  
2. T2=24 hrs (+/ - 2 hrs) 
3. T3=72 hrs (+/ - 2 hrs) 
4. T4= 120hrs (+/ - 12hrs) 
 
4.5.2 Specimen samples  
At the T1, T2, T3 , and T4  time point s, blood will be sent for  complete blood count (including 
hemoglobin, white blood cell count, platelet count), a serum chemistry (including sodium, 
potassium, chloride, bicarbonate, blood urea nitrogen, creatining, glucose, aspartate transaminase, 
alanine transaminase, and total b ilirubin), and a  venous  blood gas to measure lactate. These tests 
will be performed by the clinical laboratory at each site. As many of these laboratory tests are 
commonly obtained for clinical purposes, these tests do not need to be repeated if a result i s 
available from the clinical care of the participant  within 2 hours  of the time point  (or within 12  hours 
of the T4 time -point) .  
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 14 of 34  
In addition to traditional clinical markers , blood will be obtained for future biomarker analysis  
(including inflammatory bi omarkers, markers of endothelial function, and markers of mitochondrial 
function),  and measurement of vitamin C, vitamin B1, and cortisol levels.  The total volume of blood 
that may be drawn for a participant at each time point will not exceed 60mls . Levels of vitamin C, 
vitamin B1, and cortisol will be measured at time T1 and time T3 only. 20ml of urine will be collected  
for future biomarker analysis  at T1, T2, and T3 . 
 
If performed as part of standard -of-care, results of urinalysis and urine sediment  testing will be 
collected prior to enrollment .  
 
4.5.3 Biomarker tube initial processing  and shipping  
Please see accompanying blood collection standard operating procedure for full details. In brief, 
15ml of blood will be dra wn into EDTA tube s and 10ml  of blood will be drawn into a  corvac tube. 
From one of the EDTA tubes, 3ml of whole blood will be initial ly drawn and separated into 3x 1ml 
aliquots. Plasma will then be isolated from the EDTA tube (s) and aliquoted into cryovials as follows: 
4x 0.5ml aliquots and the remainder in 1ml aliquots. Serum will then be isolated from the corvac 
tube, and separated in to 1ml aliquots. Cryovials will be protected from light and frozen at -80°C until 
processing. An additional 20ml of urine will also be collecte d, centrifuged, and separated into 1ml 
aliquots then frozen at -80°C until processing . 
 
Sites will be expected to ship frozen samples to the coordinating center after every 5 enrollments. 
The coordinating center will assist with all shipping procedures.  
 
4.6 Study flow diagram  
 
 
 
4.7 General Sepsis Management  
Investigators should follow local sepsis management guidelines. No specific sepsis bundle is 
required by this study, however the early administration of antibiotics, maintenance of a mean 
arterial pressure ≥65 mmHg  with a combination of volume resuscitation and vasopressors, and early 
source control are recommended —as detailed in the Suriving Sepsis Guidelines .55 Elements of 
sepsis care should be report ed on the online case report form (CRF).  

 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 15 of 34  
4.8 Glucometer use during the study period  
High dose vitamin C has been shown to falsely elevate glucose level readings whe n measured with 
certain point -of-care glucometers employing glucosedehydrogenase -pyrroloqui noline quinone 
amperometric methods56. Some commonly used gl ucometer brands using this approach include 
Accu -Chek (Roche Diagnostic) and Optium (Abbott Diabetes Care) (but not StatStrip; Nova 
Biomedical) . While the effects of high -dose vitamin C on glucometer readings have been seen 
primarily at higher doses of vit amin C than are intended for use in this trial,56 we recommend that 
sites explore what glocumeters are in use in local ICUs. If locally used glucometers may be 
impacted by high serum concentrations of vitamin C (as determined by the manufacturer), we 
recommend that clinical teams caring for enrolled participants be alerted to the possibility of falsely 
elevated blood -glucose levels when measured by glucometer. If there is a clinical concern about a   
glucose reading  obtained via glucometer , a serum glucose should be obtained which w ill not be 
impacted  by vitamin C. In the event of an emergency related to suspected hypoglycemia, glucose 
should be immediately given while a serum glucose level is pending.  
 
5. OUTCOMES  
5.1 Definitions  
5.1.1 Primary Outcome  
The primary outcome will be the absolute change  in the Sequential Organ Failure Assessment 
(SOFA] ) score from enrollment (time=0)  to 72 hours after drug administration . The SOFA score will 
be defined using  a modification in which the SaO2/FiO2 ratio is sub stituted for the PaO2/FiO2 ratio 
as has been previously described.57,58 This modified score will be used so that participant s without 
an existing arterial catheter can be spared arterial puncture.  
 
Points  SaO2*/FiO2§ Blood Pressure  GCS‖ Bilirubin  
(mg/dL)  Creatinine 
(mg/dL)  Platelets 
(x103µL) 
1 <400 < 70 mm/Hg  13–
14 1.2–1.9 1.2 – 1.9 <150  
2 
<326 dopamine ≤ 5  µg/kg/min  or 
dobutamine  
(any dose)  10–
12 2–5.9 2.0 – 3.4 <100  
3 <236 (and receiving 
invasive or non -invasive 
mechanical ventilation)  dopamine > 5µg/kg/min, 
epinephrine/norepinephrine  
≤ 0.1 µg/kg/min  6–9 6–11.9 3.5 – 4.9 
Or 
UOP†<500ml/day  <50 
4 
<151(and receiving 
invasive or non -invasive 
mechanical ventilation)  dopamine >  15, 
epinephrine/norepinephrine  
> 0.1 µg/kg/min  <6 >12 > 5.0  
UOP†<200ml/day  
Or receiving 
renal 
replacement 
therapy  <20 
*SaO2=Oxygen saturation (%);  § = Fraction of inspired oxygen (%); ‖ = Glasgow Coma Scale; † = Urine Output  
Fio2 will be determined by using either the set FiO2 (for patients receiving invasive or non -invasive 
mechanical ventilation) or by adding 3% FiO2 for each liter/minute of suppleme ntal oxygen added 
up to 100% FiO2 (for patients not receiving m echanical ventilation). Patients with an SaO2/FiO2 
ratio <236 who are not receiving invasive or non -invasive mechanical ventilation , will be assigned a 
score of 2.  
 
5.1.2 Key Secondary Outcomes  
Incidence of Acute Renal Failure  – Renal failure will be defined as the development of Kidney 
Disease Improving Global Outcomes [KDIGO] Stage 3 acute kidney injury  during the index ICU stay  
after study enrollment .58 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 16 of 34  
KDIGO Stage  Serum creatinine criteria  Urine output criteria  
1 Increase in serum creatinine of 
more than or equal to 0.3 mg/dl (≥ 
26.4 μmol/l) or increase to more 
than or equal to 150% to 200% (1.5 - 
to 2-fold) from baseline  Less than 0.5 ml/kg per hour for 
more than 6 hours  
2 Increase in serum creatinine to 
more than  200% to 300% (> 2 - to 3-
fold) from baseline  Less than 0.5 ml/kg per hour for 
more than 12 hours  
3 Increase in serum creatinine to 
more than 300% (> 3 -fold) from 
baseline (or serum creatinine of 
more than or equal to 4.0 mg/dl [≥ 
354 μmol/l] with an acute  
increase of at least 0.5 mg/dl [44 
μmol/l])   Less than 0.3 ml/kg per hour for 
24 hours or anuria for 12 hours  
OR 
New renal replacement therapy 
(RRT)  
 
30-Day Mortality  – Mortality at 30 -days.  This will be assessed by review of the medical records if the 
participant  remains in the hospital  or if the participant  expired while in the hospital. If the participant  
was discharged, 30 -day mortality will be assessed by contacting the participant  by ph one or by 
searching the National Center for Health Statistics (NCHS) National Death Index (NDI) consistent 
with a recent multicenter phase III trial in sepsis.23 Phone calls will be made by the research team at 
each site.  
 
5.2 Rationale for Outcomes  
Change in SOFA score : Organ failure is highly associated with mortality60 and improvement in 
organ function is a key goal for critical care phys icians. In the study by Marik et al.36, participant s 
who received the 3 -drug regimen had substantial improvements in the trajectory of organ failure 
over the first 72 -hours of their ICU stay. If the combination of vitamin C, hydrocortisone,  and vitamin 
B1 can improve organ function in the first 72 -hours following ICU admission, we believe that 
clinicians will likely quickly adopt this safe and inexpensive therapy. Importantly, this outcome can 
be measured early in the hospital stay and is th erefore less likely to be affected by other potential 
elements of hospital care that can affect more distal outcomes (e.g., mortality).  
 
Kidney Injury: Renal failure has been estimated to occur in 23% of participant s with sepsis  and 
over 50% of participant s with septic shock.61 In studies of participant s with septic shock, there is a 
step-wise increase in mor tality with worsening acute kidney injury (AKI).62 In addition, many 
participant s who experience renal injury during septic shock do not recover renal function prior to 
hospital discharge and may require long term dialysis. As both data from the study by Marik et. al.36 
and a separate study of vitamin B1  in septic shock38 have shown substantial improvements in renal 
outcomes,  kidney failure is a natural secondary outcome and one that could change practice 
independently from other factors – in other words, many clinicians would likely provide this therapy if 
they knew that kidney function could be protected, since this organ is  vital to long -term health.  
 
Mortality:  Finally, we will measure 30 -day mortality. We anticipate that the combination of vitamin 
C, hydrocortisone, and vitamin B1 will reduce mortality in this high -risk population .  
 
5.3 Additional Secondary Outcomes  
5.3.1  Additional secondary outcomes  
Additional secondary outcomes will include length of ICU stay, length of hospital stay, ventilator -free 
days  over the first 7 -days after enrollment , shock -free days  over the first 7 -days after enrollment , 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 17 of 34 and the incidence  of delirium on day #3 of the ICU stay  (as assessed using the Confusion 
Assessment Method [CAM -ICU] system ).63 Sites at which the CAM -ICU is performed daily as part of 
standard -of-care should assess whether delirium occurs on any day during  the initial ICU stay.  See 
Appendix #2.   
 
5.3.2 90-day follow -up for Quality of Life assessment  
Sites may choose to participate in a long -term outcomes substudy  exploring the effects of ascorbic 
acid, hydrocortisone, and thiamine vs. placebo on quality of life following sepsis. If a site chooses to 
participate, a trained research assistant/investigator at the site (who is blinded to treatment arm) will 
contact all participants who were alive at 30 -days, and perform the SF -36 at day 90 following 
enrollment. The SF -36 is a 36-Item Short -Form Health Survey (SF -36), a validated survey of general 
quality of life in adults, can be administered in person or over the telephone by research personnel. It 
measures eight different dimensions: physical functioning, bodily pain, role limitations due to physical 
health problems, role limitations due to personal or emotional problems, emotional well -being, social 
functioning, energy/fatigue, and general health perceptions, as well as one question asking abo ut 
perceived changes in health. The telephone version of the 36 -Item Short -Form Health Survey has 
been validated64,65 and used in sepsis.66-69  
 
5.4 Safety  
5.4.1 Definitions  
The following definitions  will be used70:  
 
Adverse event : any untoward medical occurrence in a participant  to whom a medicinal product is 
administered and which does not necessarily have a causal  relationship with this treatment  
 
Serious adverse event : any untoward medical occurrence that at any dose requires in participant  
hospitalization or prolongation of existing hospitalization, results in persistent or significant disability 
or incapacity, results in a congenital anomaly or birth defect, is life -threatening, or results in death  
 
Unexpected serious adverse event : a seri ous adverse reaction, the nature, severity or outcome of 
which is not consistent with the reference safety information  
 
 
5.4.2 Specific adverse event  data collection  
To assess specific amd potentially  serious adverse  event s that may be related to the combination of 
the study medications , we will collect data on the following:  
 
Serious Adverse Event  Definition  
Hyperglycemia  Serum glucose >300mg/dl in the first 120-hours after 
enrollment  
Hypernatremia  Serum sodium (> 1 50 mmol/L) occurring in the first 120-
hours after enrollment  
New Infection  As determined by the site principal investigator at each 
site. Should be a new organism or site of infection and 
believed to be  unrelated to the initial presenting 
infectious source.  Many will have the initiation of new 
antibiotics or a change in antibiotics.  Catheter -site 
Lung  
Gastrointestinal  
Urinary tract  
Other  
Serious allergic reaction  Anaphylaxis or other allergic reaction requiring systemic 
corticosteroids.  Allergic reaction should be related (or 
suspected to be related) to the study medicaiton   
Renal calculus  Development of a renal calculus between enrollment 
and 30 -day follow -up (based on question asked during 
follow -up phone call) . 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 18 of 34  
5.4.3 Adverse Event  Reporting  
All unexpected serious adverse events thought to be related to the study drug, and any 
unexpected fatal or life -threatening adverse events thought to be related to the study drug 
will be recorded in the online CRF, reported direc tly to the coordinating center, and reported 
to the appropriate IRB  shortly following the event per local protocol. In addition, unexpected 
serious adverse events related to the study drug will be undergo expedited reporting to the 
DSMB within 7 days of th e coordinating center becoming aware of the event. The DSMB will 
additionally review all adverse events in aggregate after every 50 patients are enrolled.  
 
Adverse events will additionally be reported to the FDA as outlined in 21CFR312.32 and 
summarized below:  
a. All unexpected fatal or life -threatening adverse events thought to be related to the 
study drug will be reported to the FDA within 7 calendar -days of w hen the ACTS 
team is made aware of the event.  
b. All unexpected serious adverse events thought to be related to the study drug will be 
reported to the FDA within 15 calendar -days of when the ACTS team is made aware.  
c. All serious unexpected adverse events, and  any unexpected fatal or life -threatening 
events thought to be related to the study drug, will be reported back to all site 
investigators within 15 calendar -days of the event.  
d. The ACTS team will periodically review all published information relating to the  safety 
of each element of the drug combination. Any concerning safety information obtained 
from this review, or otherwise obtained (e.g. from unpublished scientific papers), will 
be reported to the FDA within 15 calendar -days.  
 
5.4.5 Safety Monitoring Lab s 
As detailed above, safety monitoring labs will be obtained at 120-hours, after completion of the 
study protocol.  
 
6. SAMPLE SIZE CALCULATION AND STATISTICAL ANALYSIS PLAN  
6.1 Sample size calculation  
The study has been powered to have at least 80% power for the primary outcome and all key 
secondary outcomes as follows:  
 
SOFA Score : Based on preliminary data36, we conservatively anticipate a decrease in SOFA score 
of 6 (standard deviation [SD]: 4) in the treatment group and 4 (SD: 2) in the placebo group. With 
these estimates, enrollment of 200 participant s (100/arm)  at an alpha of 0.05 and using a t -test 
with unequal variance, the trial will provide > 99% power to detect a statistical significant difference 
between groups.  
 
Kidney Injury:  Based on preliminary data from our study of vitamin B1  in septic shock,38 we 
anticipate that 30% of participant s in the treatment group and 55% in the pl acebo group will have 
renal failure which will result in a 94% power for this outcome.  This calculation and following 
calculation were performed using the Fisher’s exact test.  
  
Mortality:  Based on preliminary data36,37,71, we anticipate that the control group will have a mortality 
of 40%. We estimate a t reatment effect of 50% (risk ratio: 0.50) resulting in a mortality of 20% in the 
treatment group. With these estimates, 182 participant s will lead to 80% power. To further increase 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 19 of 34 the trial’s power  and due to potential loss -to-follow -up, we will aim to en roll 200 participant s. These 
estimates are conservative compared to the Marik et al. study which found a treatment effect 
corresponding to a risk ratio of 0.21 which persisted in adjusted analysis.36  
 
Sample Size Adjustment  
 
If after 100 patients are enrolled, the overall change in SOFA score is less than anticipated in the 
above power analysis and/or the renal failure event rate or mortality rate is lower than predicted, the 
enrollment target of 200 patients may be adjusted  accordingly  so as to improve  power for the 
primary outcome and all key secondary  outcomes at the end of the trial period.  Specifically, we will 
aim to maintain ≥90% power to detect a 2 -point difference in ΔSOFA score (using variance seen for 
the full cohort ) and ≥80% power to detect a 50% treatement effect on mortality. Whether to  increase 
the study sample size, and the degree of sample size increase,  will be  decided on  by the  blinded  
Steering Committee who will not have access to data stratified by treatmen t group . The Steering 
Committee will take into account logistical and financial considerations when updating the 
enrollment target.  
 
6.2 Statistical analysis plan  
6.2.1 General considerations  
The statistical analyses and reporting will adhere to the CONSORT guidelines.72,73 All test s will be 
two-sided, a p -value < 0.05 will be considered significant, and all confidence intervals will have 95% 
coverage. A ll analyses will be conduct ed on a modified intention -to-treat basis only including 
participant s receiving  at least  the first dose of the study  medications . In a double -blind trial, this 
approach is unbiased while increasing precision.74 The two groups will be compared in relation to 
baseline characteristics using descriptive statistics.  
 
The persons conducting the statistical analysis will be blinded to the randomized allocation. Groups 
will be designated as “A” and “B”  until all pre -specified analyse s are performed and shared with all 
authors and the Data Safety Monitoring Board.  
 
6.2.2  SOFA score and renal failure  
The change in SOFA score will be calculated and compared between groups using the Wilcoxon 
Rank Sum test ( if the change is not normally distributed ) or by a t -test if the change is  approximately  
normally distributed . Fisher’s exact tests will be used to compare the incidence of renal failure 
during the index ICU stay . 
  
If a participant  expire s prior to the 72 -hour time point, SOFA scores w ill be imputed based on a pre -
defined plan as follows. If a participant expires  before 24-hours has elapsed,  a 20% increase from 
baseline will be  imputed . If a participant  expires between 24-hours and 48 -hours,  a 15% increase 
from the 24 -hour time point will be imputed . If a participant  dies between 48-hours and 72 -hours,  a 
20% increase from the 24-hour time point will be  imputed. Sensitivity analyses w ill be performed using 
various other imputation techniques.  Specifically, we will perform 1) a sensitivity analysis in which the 
worst possible SOFA score (score of 24) is imputed for those participant s who expire , 2) a sentivity 
analysis in which the last SOFA score for participant s who expire will be carried for ward , and 3) a 
sensitivity analysis in which only those patients who survive to 72 -hours are included . These 
sensitivity analyses were chosen to model ‘worst -possible’  and ‘best -possible’ scenarios . For the 
secondary outcome of renal failure, participant s who expire during their ICU stay  will be assessed to 
have developed renal failure if they demonstrated any degree of unresolved KDIGO acute kidney 
injury prior to death. If there was no evidence of acute kidney injury prior to death  or if kidney injury 
had fully resolved , these participant s will be assessed as not having developed renal failure.  
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 20 of 34  
6.2.3 30-day mortality  
Survival until 30 days will be analyzed using survival analysis. Participant s lost to follow -up will be 
censored and the censoring will be assumed non -informative. Results will be presented with 
Kaplan -Meier curves and the groups compared using the log -rank test.75 Hazard rati os with 95% 
confidence intervals will be obtained using Cox’s proportional hazards models.76 The proportional 
hazards assumption will be verified by visual inspection of the Kaplan -Meier curves and statistically 
by including a produ ct term (i.e. “interaction”) between the treatment group variable and the natural 
logarithm of time in the model.77 If the p roportional hazards assumption is not met, only the Kaplan -
Meier curves and the p -value from the log -rank test will be presented.  
 
Adverse events and other binary outcomes will be presented and analyzed like renal failure.  
 
6.2.4 Additional Secondary Analy ses 
Both ICU and hospital length of stay will be compared using Wilcoxon Rank Sum test s. Ventilator 
and shock free days  over the first 7 -days after enrollment  will likewise be compared using the 
Wilcoxon Rank Sum  given that the data will likely be not normally distributed. In these latter two 
analyses, patients who expire prior to 7 -days will be assessed to have 0 ventilator or shock free 
days if they had died while on a ventilator or vasopressor respectively. The  incidence of delirium will 
be compared using the Fisher’s exact test.  For the quality -of-life outcome (i.e. 90 -day SF -36), the 
primary analysis will only include patients with available data. As a secondary analysis, multiple 
imputation will be used to es timate SF -36 scores in all patients not known to be dead at 90 -days. 
 
6.2.5 Subgroup analyses  
The analysis will include three  pre-defined subgroup analyses  for the primary and key secondary 
outcomes  according to 1) participant s with initially high SOFA scores (≥ 9). This cut -off was chosen 
to represent a population with a ≥50% predicted likelihood of mortality78 2) baseline vitamin B1  
deficiency and 3) baseline adrenal insufficiency. We will not plan to perform a subgroup analysis 
according to vitamin C deficiency, as prior work has shown that the vast majority of participant s with 
septic shock have vitamin C levels below the reference range.36 Vitamin B1  deficiency will be 
defined as a plasma vitamin B1  level ≤ 7 nmol/L as has been previously described.37 Adrenal 
insufficiency will be defined as a cortisol level <10µg/dL.43 The trial is not powered  to detect 
subgroup differences and these wil l be considered exploratory and hypothesis generating.    
 
6.2.6 Statistical stopping criteria  
Since the primary outcome is not mortality, there will be no formal stopping criteria for efficacy. 
There will be no predefined stopping criteria for futility s ince enrollment of the full cohort might allow 
for detection of effic acy in subgroups or in other  outcomes even if the primary outcome is negative.  
 
7. DATA COLLECTION AND MANAGEMENT  
7.1 Data collection process  
Data collection will be the responsibility of the individual site investigators with oversite from the trial 
coordinating center. Most variables  (i.e. demographics, sepsis characteristics and laboratory 
results) will be obtained prospectively from the elec tronic medical record. 30-day follow -up 
regarding safety and mortality end -points will be obtained  via telephone call post -discharge (unless 
the participant  remains in the hospital at 30 -days) . Data will be entered directly into the  online  
database softwar e (see below ).  
 
7.2 Variables  
Will be provided on the online CRF. A PDF version is available upon request.  
 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 21 of 34 7.3 Data quality and validity  
Data quality and validity will  be optimized by using a detailed data dictionary  which will be 
distributed to all sites . Data quality will be monitored both centrally by the coordinating site and 
locally by each site principal investigator.  
 
7.4 Data storage and security  
The database application we will use is REDCap  Cloud  (https://www.redcapcloud.com/) . REDCap  
Cloud  is a professional database that provides a user -friendly interface. The REDCap  Cloud  data 
management system is secure, fully compliant with all regulatory guidelines, and includes a 
complete audit -trail for dat a entry validation.  Through these mechanisms, as well as relevant 
training for all involved parties, participant  confidentiality will be safeguarded.  All members of the 
research team will be required to complete standardized training in REDCap cloud, which  will be 
documented within the software.   
 
The consent form  and other trial documents  for each participant  will initially be stored in a secure, 
locked place at the individual sites. Participating sites will be responsible for maintaining their own 
trial d ocuments and study materials ( e.g. signed ICFs, site logs etc ). Trial documents generated at 
the Coordinating Center will be maintained the Coordinating Center. Following completion of the 
trial, documents will be maintained for a period of at least 2-years at each site per FDA regulations 
(or longer depending on lo cal IRB guidelines) . 
 
8. ETHICAL CONSIDERATIONS  
8.1 Risks and Benefits   
8.1.1 Potential benefits  
Potential Benefits to Individual Participant : Assuming our hypothesis is correct and our results are 
comparable to those previously published36, individual participant s enrolled in our study and 
randomized to the treatment arm will benefit from a better trajectory of organ failure and i mproved 
mortality. As many participant s who survive an initial episode of sepsis will have a future admission for 
sepsis, participant s participating in this study but randomized to the placebo arm may see a future 
benefit from knowledge gained.  
 
Potential Benefits to Society: Septic shock remains a highly morbid clinical condition for which there 
is no specific therapy. Our study, assuming our hypothesis is confirmed, will provide strong support for 
the widespread adoption of vitamin C, corticosteroids, and  vitamin B1  for participant s with septic 
shock. This, in turn, will significantly improve participant  outcomes and reduce the global burden of 
death related to septic shock. Thus, even if participant s are randomized to the placebo arm, their 
involvement wi th this study has tremendous potential benefits for society as whole. If vitamin C, 
corticosteroids, and vitamin B1  are found to be neutral or harmful (the latter being highly unlikely), 
society will benefit as the study will likely prevent the widespread dissemination of an ineffective 
medication combination .  
 
8.1.2 Potential harms  
Study Drug  
Vitamin C  – Ascorbic acid is a water -soluble essential vitamin that is safe even at high doses. 
Nevertheless, adverse effects related to high -dose ascorbic acid have been described. These 
adverse effects include diarrhea/abdominal bloating, increased oxalate excret ion, iron overload in 
participant s with hemochromatosis, and hemolysis in participant s with G6PD deficiency.79  We 
exclude participant s with known renal failure,  known G6PD deficiency, or known hemochromatosis  
to limit these potential risks . We will additionally exclude participant s with known allergy to ascorbic 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 22 of 34 acid. Ascorbic acid has additionally been used in at least 3 clinical trials in critically -ill populations 
without major associated adverse effect.40-42 
 
Hydrocortisone – Hydrocortisone is a well -established medication for the treatment of refractory 
shock in sepsis. Some studies (e.g. CORTICUS) have found an increased incidence of secondary 
infection in participant s with septic shock who receive steroids.46 This finding has not been 
replicated in other large trials of corticosteroids for sepsis.47 Additional hypothetical risks to the 
administration of hydrocortisone to participant s with septic shock (e.g. increased gastro -intestinal 
bleeding, muscle weakness , and delirium ) have not been found in clinical trials of co rticosteroids in 
sepsis .46,47 Finally, hydrocortisone may increase the risk of hyperglycemia  and hypernatremia .  
 
Hydrocortisone will not be tapered in this study as prior studies have shown benefit with 
corticosteroids in septic shock without a taper.80 In addition, a recent large trial of corticosteroids in 
septic shock (ADRENAL, NEJM 2018) randomized patients to 7 -days of corticosteroids or placebo 
and did not include a taper. In that trial there was no reported difference in rates of recurrent shock.  
 
Vitamin B1  – The only potential  serious  side effect  that has been  reported  from vitamin B1  
administration  is an extremely  rare anaphylactic  reaction  (1:250,000 cases ) and this might  not even  
be of issue  with the current  manufactured  version  of vitamin B1  in the United  States . The risk of an 
anaphylactic  reaction  was associated  with a vitamin  complex  dispensed  in Europe , and whether  
vitamin B1  was the actual  offending  agent  remains  unknown ; however , this 0.0004% theoretical  
chance  of an adverse  reaction  is incredibly  low. In a series  of 989 participant s in the United  States  
who received  intravenous  vitamin B1 , none  had an anaphylactic  reaction  and the only reported  side 
effects  were  minor  consisting  of transient  local irritation  or in one case  pruritus  (0.093%).81 Further 
safety  data comes  from the clinical  use of intravenous  vitamin B1  at our coordinatin g site.  At Beth 
Israel Deaconess Medical Center  (BIDMC, coordinating center) vitamin B1  is provided  liberally  for 
participant s with nutritional  deficiency  – for example , BIDMC  has administered  intravenous  vitamin 
B1 in over 8,000 separate  participant  encounters  from 2002 until present . Despite  this heavy  usage , 
no adverse  reactions  were  reported  in any of the 8,000 participant  encounters .    
 
The combination of vitamin C , hydrocortisone and vitamin B1  – To date, the only study of the 
combination of vitamin C , hydrocortisone and vitamin B1  was the above referenced study by Marik 
et. al.  
 
All procedures will take place at the study site. All research procedures an d monitoring will be 
conducted  by experienced personnel, and participant s will be in the ICU given critical illness . This 
permits closer observation and more detailed monitoring by clinicians familiar with the care of 
participant s experiencing and resuscit ated from septic shock.  
 
Blood Collection  
Most participant s will have existing venous or arterial catheters in place and we will be able to collect 
blood from these ports, essentially eliminating the risks associated with blood collection. In the very 
rare case that a participant  does not have an indwelling line, the risk of venipuncture is extremely low, 
and will not exceed the risk of clinical blood draws the participant  will already be receiving.  
 
Loss of Confidentiality  
All measures will be taken to ensure that no confidential information is released. All participant  
information will be stored in a password protected database to which only study investigators will 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 23 of 34 have access. Additionally, all hard copies of study data w ill be kept in a locked office accessible only 
to study investigators. Thus, the risk of loss of confidentiality is very low.  
 
9. MONITORING  
9.1 Institutional Review Board (IRB)  
The study will be reviewed and approved by the IRB at each participating site.   
 
9.2 Data Safety and Monitoring Board (DSMB)  
The DSMB will be responsible for safeguarding the interests of trial participants, assessing the 
safety and efficacy of the interventions during the trial, and for monitoring the overall conduct of the 
clinical trial. The DSMB  will consist of three  clinicians with critical  care experience in the 
management of septic participant s. An independent  biostatistician/epidemiologist  will prepare all 
DSMB reports . The DSMB members  will be chosen such to avoid any financial or intellectual 
conflicts of interest. The DSMB  will review deidentified data after every 50 participant s are enrolled 
to assess for safety; unless there are group differences necessitating unblinding (as determined by 
the DSMB ), the DSMB  will be blinded to treatment groups.  The trial will continue while the DSMB  
review data.  After each  review, the DSMB  will create a short report to the steering committee with 
recommendations for continuation, modifications, or termination of the trial. Criteria for 
recommending termination w ill be at the discretion of the DSMB and there will be no formal 
statistical criteria for termination due to efficacy or safety . A detailed charter for the DSMB will be 
provided.  
 
DSMB Members  
Clifton Callaway, MD, PhD  
University of Pittsburgh  
400A Iroqu ois 
Pittsburgh, PA 15260  
(412) 647 -8287  
callawaycw@upmc.edu  
Professor (tenured) of Emergency Medicine; Executive Vice -Chair of Emergency Medicine; UPMC 
Professor of Emergency Medicine Research  
Expertise: Cardiac Arrest/Clinical Trials  
 
Taylor Thompson, MD  
Massachusetts General Hospital  
55 Fruit Street  
Boston, MA 02114  
(617) 724 -7823  
tthompson1@partners.org  
Professor of Medicine, Harvard Medical School  
Director, Critical Care Translational Rese arch, Pulmonary/Critical Care Unit, MGH  
Medical Director, ARDS Network Clinical Coordinating Center  
Expertise:  Sepsis/Clinical Trials  
 
Shahzad Shaefi, MD MPH [DSMB Chair]  
Beth Israel Deaconess Medical Center  
One Deaconess Raod  
Boston, MA 02115  
(617) 355-6286  
sshaefi@bidmc.harvard.edu  
Attending Physician, Department of Anesthesia, Critical Care and Pain  
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 24 of 34 Expertise:  Critical Care Medicine  
 
10 CLINICAL MONITORING PLAN  
The detailed clinical monitoring plan has been developed and is available from the Coordianting 
Center upon request.  
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 25 of 34 11. TIMELINE  AND ENROLLMENT   
11.1 Timeline  
 Pre-trial Months 0 -5 Months 6-11 Months 1 2-18 
Funding                     
Protocol development and 
modifications                     
FDA IND approval                     
Ethical approval                     
Registration with 
Clinicaltrials.gov                     
Creation of data dictionary                     
Creation of randomization 
list                    
Site start -up                    
Education of site 
personnel                     
DSMB monitoring                     
Enrollment and 
assessment of outcomes                     
Cleaning and closing of 
the database                     
Unblinding & Data analysis                     
Main manuscript writing                     
Publication and 
presentation of results                     
 
11.2 Screening & Enrollment  
Enrollment at each site will be continuously monitored by the site invest igator  and the  principal 
investigator.  Each site will be expected to maintain a screening log including all participant s who 
meet all eligibility  criteria at that site. A standardized screening log will be provided to each site  via 
RedCap Cloud —thus allowing for continu ous updating of the screening log  and will allow capture of 
all screening failures .    
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 26 of 34  
Enrollment will be competitive (i.e. without specific enrollment caps). Number of enrollments at each 
site will be shared with all sites on a monthly basis.  Sites will be expected to complete all elements 
of the online CRF within 48 -hours of each time point. In the case that a site continuously 
underperforms despite troubleshooting and feedback, the steering committee will evaluate whether 
enrollment will continue at tha t site.  
 
12. FUNDING  
Funding for the present trial is provided by the Good Ventures Foundation 
(http://www.goodventures.org/ ). The funding agenc y will have no role in the design and conduct of 
the study , collection, management, analysis, and interpretation of the data , preparation, review, or 
approval of the manuscript , or the decision to submit the manuscript for publication.  
 
13. PUBLICATION  
The manuscript will adhere to the CONSORT guidelines.72,73 The principal investigator will be 
responsible for assigning authorship position and will follow aut horship guidelines from the 
International Committee of Medical Journal Editors.82 At a minimum, all members of the Steering 
Committee and all site Principal Inv estigators (for sites enrolling at least 1 0 participant s) will be 
included in the primary author list. The main results will be presented at an international conference. 
The trial results will be shared with participating sites and via press releases but not directly with the 
participant s. 
 
14. DATA SHARING  
Six months after the publication of the last results, all de -identified individual participant  data will be 
made available for data sharing.83 Procedures, including re -coding of key variables, will be put in 
place to allow for complete de -identification of the data. All relevant trial -related documents, 
including the protocol, data dictionary, and the main statistical code, will be shared alo ng with the 
data. There will be no predetermined end date for the data sharing. Data will be available for any 
research purpose to all interested parties who have approval from an independent ethics review 
committee and who have a methodological sound prop osal as determined by the steering 
committee of the current trial. Interested parties will be able to request the data by contacting the 
principal investigator. Authorship of publications emerging from the shared data will follow standard 
authorship guidel ines from the International Committee of Medical Journal Editors82 and might or 
might not include authors from the steering committee depending on the nature of  their involvement.  
 
15. TASKS AND RESPONSIBILITIES  
Principal investigator and sponsor : Overall responsibility for protocol development, funding, budget 
overview, data dictionary development, ethical approval, trial registration, daily management, trial 
oversight  and collection of adverse events , contact to the pharmacy, contact to Good Clinical 
Practice monitoring unit and the data and safety monitoring board, assessment of overall 
recruitments, potential recruitment of additional sites , data analysis, and dissemination and 
presentation of results .  
 
Steering committee : Protocol development, funding, budget overview, data dictionary development, 
trial oversight, dissemination of results, responsibilities as principal investigator for sho rt time 
periods .  
 
Site investigators : Responsible for site -specific enrollment, evaluation of eligible patients not 
included, education of personnel at participating sites, reporting of site -specific issues or challenges 
to the principal investigator, par ticipant consent for data collectio n, collecting and reporting data 
regarding adverse drug events . 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 27 of 34  
Clinical team : Administration of the study drug, participant consent for data collection .  
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 28 of 34 References  
1. ICH Harmonised Tripartite Guideline. Integrated Addendum To ICH E6(R1): Guideline For Good 
Clinical Practice E6(R2). 2016; 
http://www.ich.org /fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Step
_4.pdf . Accessed June 30, 2017.  
2. ICH Harmonised Tripartite Guideline. General Considerations for Clinical Trials E8. 1997; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E8/Step4/E8_Gui
deline.pdf . Accessed June 30, 2017.  
3. ICH Harnomised Tripartite Guidelines. Statistical Principles for Clinical Trials. 1998; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Gui
deline.pdf . Acce ssed June 30, 2017.  
4. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for 
clinical trials. Ann Intern Med. 2013;158(3): 200-207.  
5. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elabor ation: guidance for 
protocols of clinical trials. BMJ. 2013;346:e7586.  
6. Fleischmann C, Scherag A, Adhikari N, et al. Global burden of sepsis: a systematic review (abstract). 
Critical Care. 2015;19 (suppl 1).  
7. Liu V, Escobar GJ, Greene JD, et al. Hospit al deaths in patients with sepsis from 2 independent 
cohorts. Jama. 2014;312(1):90 -92. 
8. Cohen J, Vincent JL, Adhikari NK, et al. Sepsis: a roadmap for future research. The Lancet Infectious 
diseases. 2015;15(5):581 -614.  
9. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for 
management of severe sepsis and septic shock: 2012. Critical care medicine. 2013;41(2):580 -637.  
10. Yende S, Linde -Zwirble W, Mayr F, Weissfeld LA, Reis S, Angu s DC. Risk of cardiovascular events in 
survivors of severe sepsis. American journal of respiratory and critical care medicine. 
2014;189(9):1065 -1074.  
11. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence. 2014;5(1):4 -11. 
12. Wintermann G B, Brunkhorst FM, Petrowski K, et al. Stress Disorders Following Prolonged Critical 
Illness in Survivors of Severe Sepsis. Critical care medicine. 2015.  
13. Goodwin AJ, Rice DA, Simpson KN, Ford DW. Frequency, cost, and risk factors of readmissions among 
severe sepsis survivors. Critical care medicine. 2015;43(4):738 -746.  
14. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long -term cognitive impairment and functional disability 
among survivors of severe sepsis. Jama. 2010;304(16):1787 -1794.  
15. Ortego A, Gaieski DF, Fuchs BD, et al. Hospital -based acute care use in survivors of septic shock. 
Critical care medicine. 2015;43(4):729 -737.  
16. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 
1979 through 2000. The New England  journal of medicine. 2003;348(16):1546 -1554.  
17. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe 
sepsis in the United States. Critical care medicine. 2013;41(5):1167 -1174.  
18. Angus DC, Linde -Zwirble WT, Lidi cker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe 
sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical care 
medicine. 2001;29(7):1303 -1310.  
19. Deans KJ, Haley M, Natanson C, Eichacker PQ, Minn eci PC. Novel therapies for sepsis: a review. The 
Journal of trauma. 2005;58(4):867 -874.  
20. Eichacker PQ, Parent C, Kalil A, et al. Risk and the efficacy of antiinflammatory agents: retrospective 
and confirmatory studies of sepsis. American journal of res piratory and critical care medicine. 
2002;166(9):1197 -1205.  
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 29 of 34 21. Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC. The next generation of sepsis clinical trial 
designs: what is next after the demise of recombinant human activated protein C?*. Critical c are 
medicine. 2014;42(7):1714 -1721.  
22. Angus DC. The search for effective therapy for sepsis: back to the drawing board? Jama. 
2011;306(23):2614 -2615.  
23. ProCess Investigators, Yealy DM, Kellum JA, et al. A randomized trial of protocol -based care for ear ly 
septic shock. The New England journal of medicine. 2014;370(18):1683 -1693.  
24. Investigators A, Group ACT, Peake SL, et al. Goal -directed resuscitation for patients with early septic 
shock. The New England journal of medicine. 2014;371(16):1496 -1506.  
25. Mouncey PR, Osborn TM, Power GS, et al. Trial of early, goal -directed resuscitation for septic shock. 
The New England journal of medicine. 2015;372(14):1301 -1311.  
26. Asfar P, Meziani F, Hamel JF, et al. High versus low blood -pressure target in patients with septic 
shock. The New England journal of medicine. 2014;370(17):1583 -1593.  
27. Caironi P, Tognoni G, Masson S, et al. Albumin replacement in patients with severe sepsis or septic 
shock. The New England journal of medicine. 2014;370(15):1412 -1421.  
28. Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for  transfusion in 
septic shock. The New England journal of medicine. 2014;371(15):1381 -1391.  
29. Abraham E, Anzueto A, Gutierrez G, et al. Double -blind randomised controlled trial of monoclonal 
antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. 
Lancet. 1998;351(9107):929 -933.  
30. Abraham E, Naum C, Bandi V, et al. Efficacy and safety of LY315920Na/S -5920, a selective inhibitor of 
14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and org an failure. 
Critical care medicine. 2003;31(3):718 -728.  
31. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human 
tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double -
blind , multicenter clinical trial. TNF -alpha MAb Sepsis Study Group. JAMA : the journal of the 
American Medical Association. 1995;273(12):934 -941.  
32. Fisher CJ, Jr., Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor 
receptor:F c fusion protein. The Soluble TNF Receptor Sepsis Study Group. The New England journal 
of medicine. 1996;334(26):1697 -1702.  
33. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of 
patients with sepsis. The Ibuprofen in Sepsis Study Group. The New England journal of medicine. 
1997;336(13):912 -918.  
34. Marti -Carvajal AJ, Sola I, Gluud C, Lathyris D, Cardona AF. Human recombinant protein C for severe 
sepsis and septic shock in adult and paediatric patients. The Cochrane database of systematic 
reviews. 2012;12:CD004388.  
35. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. 
The New England journal of medicine. 2012;366(22):2055 -2064.  
36. Marik PE, Khangoora V, Rive ra R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C, and Thiamine 
for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before -After Study. Chest. 
2017;151(6):1229 -1238.  
37. Donnino MW, Andersen LW, Chase M, et al. Randomized, Double -Blind, Placebo -Controlled Trial of 
Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study. Crit Care Med. 2016;44(2):360 -
367.  
38. Moskowitz A, Andersen LW, Cocchi MN, Karlsson M, Patel PV, Donnino MW. Thiamine as a Renal 
Protective Agent in Septic  Shock. A Secondary Analysis of a Randomized, Double -Blind, Placebo -
controlled Trial. Annals of the American Thoracic Society. 2017;14(5):737 -741.  
39. Teng J, Pourmand A, Mazer -Amirshahi M. Vitamin C: The next step in sepsis management? J Crit 
Care. 2017;4 3:230 -234.  
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 30 of 34 40. Fowler AA, 3rd, Syed AA, Knowlson S, et al. Phase I safety trial of intravenous ascorbic acid in 
patients with severe sepsis. Journal of translational medicine. 2014;12:32.  
41. Tanaka H, Matsuda T, Miyagantani Y, Yukioka T, Matsuda H, Shimaz aki S. Reduction of resuscitation 
fluid volumes in severely burned patients using ascorbic acid administration: a randomized, 
prospective study. Archives of surgery (Chicago, Ill : 1960). 2000;135(3):326 -331.  
42. Zabet MH, Mohammadi M, Ramezani M, Khalili H. Effect of high -dose Ascorbic acid on vasopressor's 
requirement in septic shock. Journal of research in pharmacy practice. 2016;5(2):94 -100.  
43. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating sepsis. 
Cochran e Database Syst Rev. 2015(12):CD002243.  
44. May JM, Harrison FE. Role of vitamin C in the function of the vascular endothelium. Antioxidants & 
redox signaling. 2013;19(17):2068 -2083.  
45. Han M, Pendem S, Teh SL, Sukumaran DK, Wu F, Wilson JX. Ascorbate pro tects endothelial barrier 
function during septic insult: Role of protein phosphatase type 2A. Free radical biology & medicine. 
2010;48(1):128 -135.  
46. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. The New 
England  journal of medicine. 2008;358(2):111 -124.  
47. Keh D, Trips E, Marx G, et al. Effect of Hydrocortisone on Development of Shock Among Patients 
With Severe Sepsis: The HYPRESS Randomized Clinical Trial. Jama. 2016;316(17):1775 -1785.  
48. Okamoto K, Tanaka H, Makino Y, Makino I. Restoration of the glucocorticoid receptor function by the 
phosphodiester compound of vitamins C and E, EPC -K1 (L -ascorbic acid 2 -[3,4-dihydro -2,5,7,8 -
tetramethyl -2-(4,8,12 -trimethyltridecyl) -2H-1-benzopyran -6 -yl hydrogen phosphate] po tassium 
salt), via a redox -dependent mechanism. Biochemical pharmacology. 1998;56(1):79 -86. 
49. Fujita I, Hirano J, Itoh N, Nakanishi T, Tanaka K. Dexamethasone induces sodium -dependant vitamin 
C transporter in a mouse osteoblastic cell line MC3T3 -E1. The British journal of nutrition. 
2001;86(2):145 -149.  
50. Donnino MW, Andersen LW, Chase M, et al. Randomized, Double -Blind, Placebo -Controlled Trial of 
Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study. Critical care medicine. 
2016;44(2):360 -367.  
51. Gioda CR, de Oliveira Barreto T, Primola -Gomes TN, et al. Cardiac oxidative stress is involved in heart 
failure induced by thiamine deprivation in rats. American journal of physiology Heart and circulatory 
physiology. 2010;298(6):H2039 -2045.  
52. Pacal L, Tomandl J, Svojanovsky J, et al. Role of thiamine status and genetic variability in 
transketolase and other pentose phosphate cycle enzymes in the progression of diabetic 
nephropathy. Nephrology, dialysis, transplantation : official publication of  the European Dialysis and 
Transplant Association - European Renal Association. 2011;26(4):1229 -1236.  
53. Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI. Stratified randomization for clinical trials. 
J Clin Epidemiol. 1999;52(1):19 -26. 
54. Johnson K, Posner SF, Biermann J, et al. Recommendations to improve preconception health and 
health care --United States. A report of the CDC/ATSDR Preconception Care Work Group and the 
Select Panel on Preconception Care. MMWR Recommendations and reports : Morbidit y and 
mortality weekly report Recommendations and reports. 2006;55(Rr -6):1-23. 
55. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for 
Management of Sepsis and Septic Shock: 2016. Critical care medicine. 2017;45(3):486 -552.  
56. Flannery AH, Bastin MLT, Magee CA, Bensadoun ES. Vitamin C in Sepsi s: When It Seems Too Sweet, It 
Might (Literally) Be. Chest. 2017;152(2):450 -451.  
57. Pandharipande PP, Shintani AK, Hagerman HE, et al. Derivation and validation of Spo2/Fio2 ratio to 
impute for Pao2/Fio2 ratio in the respiratory component of the Sequential Organ Failure Assessment 
score. Critical care medicine. 2009;37(4):1317 -1321.  
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 31 of 34 58. Grissom CK, Brown SM, Kuttler KG, et al. A modified sequential organ failure assessment score for 
critical care triage. Disaster medicine and public health preparedness. 2010;4(4):277 -284.  
59. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network : report of an initiative to improve 
outcomes in acute kidney injury. Critical care (London, England). 2007;11(2):R31.  
60. de Grooth HJ, Geenen IL, Girbes AR, Vincent JL, Parienti JJ, Oudemans -van Straaten HM. SOFA and 
mortality endpoints in randomized con trolled trials: a systematic review and meta -regression 
analysis. Crit Care. 2017;21(1):38.  
61. Schrier RW, Wang W. Acute renal failure and sepsis. The New England journal of medicine. 
2004;351(2):159 -169.  
62. Kellum JA, Chawla LS, Keener C, et al. The Eff ects of Alternative Resuscitation Strategies on Acute 
Kidney Injury in Patients with Septic Shock. American journal of respiratory and critical care 
medicine. 2016;193(3):281 -287.  
63. Ely EW, Inouye SK, Bernard GR, et al. Delirium in mechanically ventilate d patients: validity and 
reliability of the confusion assessment method for the intensive care unit (CAM -ICU). Jama. 
2001;286(21):2703 -2710.  
64. Watson EK, Firman DW, Baade PD, Ring I. Telephone administration of the SF -36 health survey: 
validation studies  and population norms for adults in Queensland. Aust N Z J Public Health. 
1996;20(4):359 -363.  
65. Garcia M, Rohlfs I, Vila J, et al. Comparison between telephone and self -administration of Short Form 
Health Survey Questionnaire (SF -36). Gac Sanit. 2005;19( 6):433 -439.  
66. Schmidt K, Worrack S, Von Korff M, et al. Effect of a Primary Care Management Intervention on 
Mental Health -Related Quality of Life Among Survivors of Sepsis: A Randomized Clinical Trial. Jama. 
2016;315(24):2703 -2711.  
67. Dinglas VD, Hopkin s RO, Wozniak AW, et al. One -year outcomes of rosuvastatin versus placebo in 
sepsis -associated acute respiratory distress syndrome: prospective follow -up of SAILS randomised 
trial. Thorax. 2016;71(5):401 -410.  
68. Zhang K, Mao X, Fang Q, et al. Impaired lon g-term quality of life in survivors of severe sepsis : 
Chinese multicenter study over 6 years. Anaesthesist. 2013;62(12):995 -1002.  
69. Wittbrodt P, Haase N, Butowska D, et al. Quality of life and pruritus in patients with severe sepsis 
resuscitated with hy droxyethyl starch long -term follow -up of a randomised trial. Crit Care. 
2013;17(2):R58.  
70. The European Parliament and the Council of the European Unit. Clinical Trials Regulation (CTR) EU 
No 536/2014. 2014; https://ec.europa.eu/health/sites/health/files/files/eudralex/vol -
1/reg_2014_536/reg_2014_536_en.pdf . Accessed July 18, 2017.  
71. Rhee C, Dantes R, Epstein L, et al. Incidence and Trends  of Sepsis in US Hospitals Using Clinical vs 
Claims Data, 2009-2014. JAMA. 2017;318(13):1241 -1249.  
72. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for 
reporting parallel group randomised trials. BMJ. 2010;340:c332.  
73. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated 
guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.  
74. Fergusson D, Aaron SD, Guyatt G, Hebert P. Post -randomisation exclusions: the inte ntion to treat 
principle and excluding patients from analysis. BMJ. 2002;325(7365):652 -654.  
75. Fleming T, Harrington D. Nonparametric estimation of the survival distribution in censored data. 
Communications in Statistics - Theory and Methods. 1984;13(20): 2469–2486.  
76. Cox D. Regression models and life tables. Journal of the Royal Statistical Society. 1972;Series 
B(20):187 –220.  
77. Kleinbaum D, Klein M. Survival Analysis: A Self -Learning Text.  3rd ed: Springer; 2013.  
78. Vincent JL, de Mendonca A, Cantrain e F, et al. Use of the SOFA score to assess the incidence of organ 
dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 32 of 34 group on "sepsis -related problems" of the European Society of Intensive Care Medicine. Critical care 
medicine. 1998;26(11):1793 -1800.  
79. Levine M, Rumsey SC, Daruwala R, Park JB, Wang Y. Criteria and recommendations for vitamin C 
intake. Jama. 1999;281(15):1415 -1423.  
80. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low do ses of hydrocortisone and 
fludrocortisone on mortality in patients with septic shock. Jama. 2002;288(7):862 -871.  
81. Wrenn KD, Murphy F, Slovis CM. A toxicity study of parenteral thiamine hydrochloride. Annals of 
emergency medicine. 1989;18(8):867 -870.  
82. International Committee of Medical Journal Editors. Defining the Role of Authors and Contributors. 
2017; http://www.i cmje.org/recommendations/browse/roles -and-responsibilities/defining -the-role-
of-authors -and-contributors.html . Accessed July 6, 2017.  
83. Taichman DB, Sahni P, Pinborg A, et al. Data Sharing Statements for Clinical Trials - A Requirement of 
the International Committee of Medical Journal Editors. N Engl J Med. 2017;376(23):2277 -2279.  
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 33 of 34 Appendices  
 
Appendix 1: Abbreviations  
ICH……………….. International Conference on Harmonization  
SPIRIT……………….. Standard Protocol Items: Recommendations for Interventional Trials  
ACT……………….. Ascorbic Acid, Corticosteroids, and Thiamine  
ESRD ……………….. End Stage Renal Disease  
SOFA ……………….. Sequential Organ Fa ilure Assessment  
IND……………….. Investigational New Drug  
FDA……………….. Food an d Drug Administration  
ICU……………….. Intensive Care Unit  
SaO2 ……………….. Oxygen Saturation  
FiO2 ……………….. Fraction of Inspired Oxygen  
GCS ……………….. Glasgow Coma Scale  
UOP ……………….. Urine Output  
RRT……………….. Renal Replacement Therapy  
CAM ……………….. Confusion Assessment Method  
NCHS ………………..  National Center for Health Statistics  
NDI……………….. National Death Index  
AKI………………..Acute Kidney Injury  
SD………………..  tandard deviation  
CRF………………..Case Report Form  
BIDMC ………………. .Beth Israel Deaconess Medical Center (Coordinating Center)  
IRB………………..Institutional Review Board  
DSMB ………………..Data Safety and Monitoring Board  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vitamin C, Hydrocortisone, and Vitamin B1 in Sepsis – version 2.3  
Page 34 of 34 Append ix 2: CAM -ICU Form  
 
 
